TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION: Form 990, tax year 2011
View the entire original 990 at ProPublica ↗
- Organization
- TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION (EIN 33-1092191)
- Tax period
- 2011-12-01 to 2012-11-30
- Filed
- 2013-10-24
- IRS object ID
- 201342979349300714
- Schema version
- 2011v1.5
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Timestamp | 2013-10-24T10:20:24-05:00 | Timestamp |
| Tax Period End Date | 2012-11-30 | TaxPeriodEndDate |
Preparer Firm PreparerFirm
Preparer Firm Business Name PreparerFirmBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1 |
Preparer Firm US Address PreparerFirmUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | TWO NORTH CENTRAL AVENUE STE 2300 | AddressLine1 |
| City | PHOENIX | City |
| State | AZ | State |
| ZIP Code | 85004 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnType |
| Tax Period Begin Date | 2011-12-01 | TaxPeriodBeginDate |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 331092191 | EIN |
Name Name
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE TRANSLATIONAL GENOMICS RESEARCH INST FDN | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| In Care Of Name | % CHARLES K COLESON | InCareOfName |
| Name Control | TRAN | NameControl |
| Phone | 6023438423 | Phone |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 445 N 5TH STREET SUITE 600 | AddressLine1 |
| City | PHOENIX | City |
| State | AZ | State |
| ZIP Code | 85004 | ZIPCode |
Officer Officer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | CHUCK COLESON | Name |
| Title | CFO | Title |
| Date Signed | 2013-10-14 | DateSigned |
Preparer Preparer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6023223000 | Phone |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax Year | 2011 | TaxYear |
| Build TS | 2016-02-25 16:41:14Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Change | X | AddressChange |
| Name Of Principal Officer Person | MICHAEL BASSOFF | NameOfPrincipalOfficerPerson |
Address Principal Officer US AddressPrincipalOfficerUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | SAME AS C ABOVE | AddressLine1 |
| City | PHOENIX | City |
| State | AZ | State |
| ZIP Code | 85004 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | 5882232 | GrossReceipts |
| Group Return For Affiliates | false | GroupReturnForAffiliates |
| Organization501c3 | X | Organization501c3 |
| Web Site | WWW.HELPTGEN.ORG | WebSite |
| Type Of Organization Corporation | X | TypeOfOrganizationCorporation |
| Year Formation | 2004 | YearFormation |
| State Legal Domicile | AZ | StateLegalDomicile |
| Activity Or Mission Description | BIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). | ActivityOrMissionDescription |
| Nbr Voting Members Governing Body | 18 | NbrVotingMembersGoverningBody |
| Nbr Independent Voting Members | 14 | NbrIndependentVotingMembers |
| Total Nbr Employees | 0 | TotalNbrEmployees |
| Total Nbr Volunteers | 95 | TotalNbrVolunteers |
| Total Gross UBI | 0 | TotalGrossUBI |
| Net Unrelated Business Txbl Income | 0 | NetUnrelatedBusinessTxblIncome |
| Contributions Grants Prior Year | 5881499 | ContributionsGrantsPriorYear |
| Contributions Grants Current Year | 5860920 | ContributionsGrantsCurrentYear |
| Program Service Revenue Prior Year | 0 | ProgramServiceRevenuePriorYear |
| Program Service Revenue CY | 0 | ProgramServiceRevenueCY |
| Investment Income Prior Year | 142156 | InvestmentIncomePriorYear |
| Investment Income Current Year | 20879 | InvestmentIncomeCurrentYear |
| Other Revenue Prior Year | 2063 | OtherRevenuePriorYear |
| Other Revenue Current Year | 433 | OtherRevenueCurrentYear |
| Total Revenue Prior Year | 6025718 | TotalRevenuePriorYear |
| Total Revenue Current Year | 5882232 | TotalRevenueCurrentYear |
| Grants And Similar Amnts Prior Year | 6629446 | GrantsAndSimilarAmntsPriorYear |
| Grants And Similar Amnts CY | 6322898 | GrantsAndSimilarAmntsCY |
| Benefits Paid To Members Prior Year | 0 | BenefitsPaidToMembersPriorYear |
| Benefits Paid To Members CY | 0 | BenefitsPaidToMembersCY |
| Salaries Etc Prior Year | 879547 | SalariesEtcPriorYear |
| Salaries Etc Current Year | 885835 | SalariesEtcCurrentYear |
| Total Prof Fundrsng Exp Prior Year | 0 | TotalProfFundrsngExpPriorYear |
| Total Prof Fundrsng Exp CY | 0 | TotalProfFundrsngExpCY |
| Total Fundrsng Exp Current Year | 1135474 | TotalFundrsngExpCurrentYear |
| Other Expense Prior Year | 587250 | OtherExpensePriorYear |
| Other Expenses Current Year | 538067 | OtherExpensesCurrentYear |
| Total Expenses Prior Year | 8096243 | TotalExpensesPriorYear |
| Total Expenses Current Year | 7746800 | TotalExpensesCurrentYear |
| Revenues Less Expenses Prior Year | -2070525 | RevenuesLessExpensesPriorYear |
| Revenues Less Expenses CY | -1864568 | RevenuesLessExpensesCY |
| Total Assets BOY | 9909027 | TotalAssetsBOY |
| Total Assets EOY | 8117853 | TotalAssetsEOY |
| Total Liabilities BOY | 2297856 | TotalLiabilitiesBOY |
| Total Liabilities EOY | 2371250 | TotalLiabilitiesEOY |
| Net Assets Or Fund Balances BOY | 7611171 | NetAssetsOrFundBalancesBOY |
| Net Assets Or Fund Balances EOY | 5746603 | NetAssetsOrFundBalancesEOY |
| Info In Schedule O Part III | X | InfoInScheduleOPartIII |
| Mission Description | BIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). | MissionDescription |
| Significant New Program Services | false | SignificantNewProgramServices |
| Significant Change | false | SignificantChange |
| Expense | 6322898 | Expense |
| Grants | 6322898 | Grants |
| Revenue | 0 | Revenue |
| Description | SEE SCHEDULE O | Description |
| Total Program Service Expense | 6322898 | TotalProgramServiceExpense |
| Described In501 C3 | true | DescribedIn501C3 |
| Schedule B Required | true | ScheduleBRequired |
| Political Activities | false | PoliticalActivities |
| Lobbying Activities | false | LobbyingActivities |
| Subject To Proxy Tax | false | SubjectToProxyTax |
| Donor Advised Funds | false | DonorAdvisedFunds |
| Conservation Easements | false | ConservationEasements |
| Collections Of Art | false | CollectionsOfArt |
| Credit Counseling | false | CreditCounseling |
| Term Or Permanent Endowments | true | TermOrPermanentEndowments |
| Report Land Bldg Equip | true | ReportLandBldgEquip |
| Report Invest Oth Securities | false | ReportInvestOthSecurities |
| Report Prog Rel Invest | false | ReportProgRelInvest |
| Report Other Assets | false | ReportOtherAssets |
| Report Other Liabilities | false | ReportOtherLiabilities |
| Report Fin48 Footnote | true | ReportFin48Footnote |
| Independent Audit Financial Stmt | false | IndependentAuditFinancialStmt |
| Consolidated Audit Financial Stmt | false | ConsolidatedAuditFinancialStmt |
| School | false | School |
| Foreign Office | false | ForeignOffice |
| Foreign Activities | false | ForeignActivities |
| More Than5000 K To Organizations | false | MoreThan5000KToOrganizations |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividuals |
| Professional Fundraising | false | ProfessionalFundraising |
| Fundraising Activities | false | FundraisingActivities |
| Gaming | false | Gaming |
| Hospital | false | Hospital |
| Grants To Organizations | true | GrantsToOrganizations |
| Grants To Individuals | false | GrantsToIndividuals |
| Schedule J Required | true | ScheduleJRequired |
| Tax Exempt Bonds | false | TaxExemptBonds |
| Excess Benefit Transaction | false | ExcessBenefitTransaction |
| Prior Excess Benefit Transaction | false | PriorExcessBenefitTransaction |
| Loan To Officer Or DQP | false | LoanToOfficerOrDQP |
| Grant To Related Person | false | GrantToRelatedPerson |
| Bsnss Rltnshp With Organization | false | BsnssRltnshpWithOrganization |
| Bsnss Rltnshp Thru Family Member | false | BsnssRltnshpThruFamilyMember |
| Officer Entity With Bsnss Rltnshp | false | OfficerEntityWithBsnssRltnshp |
| Deductible Non Cash Contributions | false | DeductibleNonCashContributions |
| Deductible Contributions Of Art | false | DeductibleContributionsOfArt |
| Terminated | false | Terminated |
| Partial Liquidation | false | PartialLiquidation |
| Disregarded Entity | false | DisregardedEntity |
| Related Entity | true | RelatedEntity |
| Related Org Controlled Entity | false | RelatedOrgControlledEntity |
| Transaction Related Entity | false | TransactionRelatedEntity |
| Transfers To Exempt Non Chrtbl Org | false | TransfersToExemptNonChrtblOrg |
| Activities Conducted Partnership | false | ActivitiesConductedPartnership |
| Schedule O Required | true | ScheduleORequired |
| Number Forms Transmitted With1096 | 4 | NumberFormsTransmittedWith1096 |
| Number W2 G Included | 0 | NumberW2GIncluded |
| Compliance With Backup Witholding | true | ComplianceWithBackupWitholding |
| Number Of Employees | 0 | NumberOfEmployees |
| Unrelated Business Income | false | UnrelatedBusinessIncome |
| Foreign Financial Account | false | ForeignFinancialAccount |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTrans |
| Taxable Party Notification | false | TaxablePartyNotification |
| Non Deductible Contributions | false | NonDeductibleContributions |
| Quid Pro Quo Contributions | false | QuidProQuoContributions |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOf |
| Funds To Pay Premiums | false | FundsToPayPremiums |
| Premiums Paid | false | PremiumsPaid |
| Indoor Tanning Services | false | IndoorTanningServices |
| Info In Schedule O Part VI | X | InfoInScheduleOPartVI |
| Nbr Voting Governing Body Members | 18 | NbrVotingGoverningBodyMembers |
| Number Independent Voting Members | 14 | NumberIndependentVotingMembers |
| Family Or Business Relationship | false | FamilyOrBusinessRelationship |
| Delegation Of Management Duties | false | DelegationOfManagementDuties |
| Changes To Organizing Docs | false | ChangesToOrganizingDocs |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuse |
| Members Or Stockholders | true | MembersOrStockholders |
| Election Of Board Members | true | ElectionOfBoardMembers |
| Decisions Subject To Approval | true | DecisionsSubjectToApproval |
| Minutes Of Governing Body | true | MinutesOfGoverningBody |
| Minutes Of Committees | true | MinutesOfCommittees |
| Officer Mailing Address | false | OfficerMailingAddress |
| Local Chapters | false | LocalChapters |
| Form990 Provided To Governing Body | true | Form990ProvidedToGoverningBody |
| Conflict Of Interest Policy | true | ConflictOfInterestPolicy |
| Annual Disclosure Covered Persons | true | AnnualDisclosureCoveredPersons |
| Regular Monitoring Enforcement | true | RegularMonitoringEnforcement |
| Whistleblower Policy | true | WhistleblowerPolicy |
| Document Retention Policy | true | DocumentRetentionPolicy |
| Compensation Process CEO | true | CompensationProcessCEO |
| Compensation Process Other | true | CompensationProcessOther |
| Investment In Joint Venture | false | InvestmentInJointVenture |
| States Where Copy Of Return Is Filed | AZ | StatesWhereCopyOfReturnIsFiled |
| Upon Request | X | UponRequest |
The Books Are In Care Of TheBooksAreInCareOf
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Person | CHARLES K COLESON | NamePerson |
| Telephone Number | 6023438599 | TelephoneNumber |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 445 N 5TH STREET STE 600 | AddressLine1 |
| City | PHOENIX | City |
| State | AZ | State |
| ZIP Code | 85004 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionA (21 entries)
| TitleTitle | Average Hours Per WeekAverageHoursPerWeek | Individual Trustee Or DirectorIndividualTrusteeOrDirector | OfficerOfficer | Reportable Comp From OrganizationReportableCompFromOrganization | Reportable Comp From Related OrgsReportableCompFromRelatedOrgs | Other CompensationOtherCompensation | Highest Compensated EmployeeHighestCompensatedEmployee |
|---|---|---|---|---|---|---|---|
| MICHAEL BASSOFF | |||||||
| PRESIDENT TGEN FOUNDATION | 24.0 | X | X | 0 | 432730 | 18358 | |
| JERRY BISGROVE | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| BENNETT DORRANCE | |||||||
| BOARD MEMBER / CHAIRMAN | 1.0 | X | X | 0 | 0 | 0 | |
| KARL ELLER | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| PHIL L FRANCIS | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| DIANE HALLE | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| MIKE INGRAM | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| CATHERINE IVY | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| KEN KENDRICK | |||||||
| BOARD MEMBER / SECRETARY | 1.0 | X | X | 0 | 0 | 0 | |
| RICHARD J LEHMANN | |||||||
| BOARD MEMBER / TREASURER | 1.0 | X | X | 0 | 0 | 0 | |
| F FRANCIS NAJAFI | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| WILLIAM J POST | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| TROY RICHARDS | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| THE HONORABLE SKIP RIMSZA | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| RAY THURSTON | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| HOWARD YOUNG | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 0 | 0 | ||
| TERESA BURLESON | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 440722 | 16059 | ||
| JEFFREY M TRENT PHD | |||||||
| BOARD MEMBER | 1.0 | X | 0 | 1085392 | 455479 | ||
| LEE T HANLEY | |||||||
| BOARD MEMBER (THRU 8/2012) | 1.0 | X | 0 | 0 | 0 | ||
| Elizabeth Montemayor | |||||||
| CFO | 1.0 | X | 0 | 244213 | 20350 | ||
| DENISE MCCLINTIC THRU 122011 | |||||||
| ASSOCIATE VICE PRESIDENT | 40.0 | 0 | 160107 | 6681 | X | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | 0 | TotalReportableCompFromOrg |
| Total Reportable Comp Frm Rltd Orgs | 2363164 | TotalReportableCompFrmRltdOrgs |
| Total Other Compensation | 516927 | TotalOtherCompensation |
| Number Individuals GT100 K | 0 | NumberIndividualsGT100K |
| Formers Listed | false | FormersListed |
| Total Comp GT150 K | true | TotalCompGT150K |
| Compensation From Other Sources | false | CompensationFromOtherSources |
| Number Of Contractors GT100 K | 0 | NumberOfContractorsGT100K |
| Government Grants | 175000 | GovernmentGrants |
| All Other Contributions | 5685920 | AllOtherContributions |
| Total Contributions | 5860920 | TotalContributions |
| Total Program Service Revenue | 0 | TotalProgramServiceRevenue |
Investment Income InvestmentIncome
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 20879 | TotalRevenueColumn |
| Exclusion | $20,879 | ExclusionAmount |
Income From Invest Bond Proceeds IncomeFromInvestBondProceeds
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Royalties Revenue RoyaltiesRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Net Gain Or Loss Investments NetGainOrLossInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Net Income From Fundraising Events NetIncomeFromFundraisingEvents
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Net Income From Gaming NetIncomeFromGaming
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Net Income Or Loss NetIncomeOrLoss
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 0 | TotalRevenueColumn |
Other Revenue Misc OtherRevenueMisc
| Field | Value | IRS element (for citing) |
|---|---|---|
| Description | ALL OTHER REVENUE | Description |
| Business Code | 900099 | BusinessCode |
| Total Revenue Column | 433 | TotalRevenueColumn |
| Exclusion | $433 | ExclusionAmount |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Revenue | 433 | TotalOtherRevenue |
Total Revenue TotalRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 5882232 | TotalRevenueColumn |
| Unrelated Business Revenue | 0 | UnrelatedBusinessRevenue |
| Exclusion | $21,312 | ExclusionAmount |
Grants To Domestic Orgs GrantsToDomesticOrgs
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 6322898 | Total |
| Program Services | 6322898 | ProgramServices |
Grants To Domestic Individuals GrantsToDomesticIndividuals
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Foreign Grants ForeignGrants
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Benefits To Members BenefitsToMembers
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Comp Current Officers Directors CompCurrentOfficersDirectors
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 661059 | Total |
| Management And General | 66106 | ManagementAndGeneral |
| Fundraising | 594953 | Fundraising |
Comp Disqual Persons CompDisqualPersons
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Other Salaries And Wages OtherSalariesAndWages
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 224776 | Total |
| Management And General | 22478 | ManagementAndGeneral |
| Fundraising | 202298 | Fundraising |
Pension Plan Contributions PensionPlanContributions
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Other Employee Benefits OtherEmployeeBenefits
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Payroll Taxes PayrollTaxes
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Management FeesForServicesManagement
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Legal FeesForServicesLegal
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Accounting FeesForServicesAccounting
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Lobbying FeesForServicesLobbying
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Fees For Services Other FeesForServicesOther
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 153551 | Total |
| Management And General | 153551 | ManagementAndGeneral |
Advertising Advertising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 30478 | Total |
| Management And General | 3048 | ManagementAndGeneral |
| Fundraising | 27430 | Fundraising |
Office Expenses OfficeExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 117417 | Total |
| Management And General | 11742 | ManagementAndGeneral |
| Fundraising | 105675 | Fundraising |
Information Technology InformationTechnology
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 25488 | Total |
| Management And General | 2549 | ManagementAndGeneral |
| Fundraising | 22939 | Fundraising |
Royalties Royalties
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Occupancy Occupancy
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 77206 | Total |
| Management And General | 7721 | ManagementAndGeneral |
| Fundraising | 69485 | Fundraising |
Travel Travel
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 26136 | Total |
| Management And General | 2614 | ManagementAndGeneral |
| Fundraising | 23522 | Fundraising |
Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Conferences Meetings ConferencesMeetings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 97308 | Total |
| Management And General | 9731 | ManagementAndGeneral |
| Fundraising | 87577 | Fundraising |
Interest Interest
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Payments To Affiliates PaymentsToAffiliates
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Depreciation Depletion DepreciationDepletion
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 5437 | Total |
| Management And General | 5437 | ManagementAndGeneral |
| Fundraising | 0 | Fundraising |
Insurance Insurance
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 0 | Total |
Other Expenses OtherExpenses (3 entries)
| DescriptionDescription | TotalTotal | Management And GeneralManagementAndGeneral | FundraisingFundraising |
|---|---|---|---|
| DUES AND SUBSCRIPTIONS | 7849 | 7849 | 0 |
| SEMINARS & EDUCATION | 1772 | 177 | 1595 |
| ALL OTHER EXPENSES | -4575 | -4575 | 0 |
Total Functional Expenses TotalFunctionalExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 7746800 | Total |
| Program Services | 6322898 | ProgramServices |
| Management And General | 288428 | ManagementAndGeneral |
| Fundraising | 1135474 | Fundraising |
Cash Non Interest Bearing CashNonInterestBearing
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 254533 | BOY |
| EOY | 49061 | EOY |
Savings And Temp Cash Investments SavingsAndTempCashInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 6186490 | BOY |
| EOY | 5252960 | EOY |
Pledges And Grants Receivable PledgesAndGrantsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 3398177 | BOY |
| EOY | 2795463 | EOY |
Accounts Receivable AccountsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -1160 | BOY |
| EOY | 0 | EOY |
Receivables From Officers Etc ReceivablesFromOfficersEtc
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Receivables From Disqual Persons ReceivablesFromDisqualPersons
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Other Notes Loans Receivable Net OtherNotesLoansReceivableNet
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Inventories For Sale Or Use InventoriesForSaleOrUse
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 5548 | BOY |
| EOY | 5548 | EOY |
Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 25252 | BOY |
| EOY | 12450 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Buildings Equipment Basis | 168169 | LandBuildingsEquipmentBasis |
| Land Bldg Equipment Accum Deprec | 167263 | LandBldgEquipmentAccumDeprec |
Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 6343 | BOY |
| EOY | 906 | EOY |
Investments Pub Traded Securities InvestmentsPubTradedSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Investments Other Securities InvestmentsOtherSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Investments Program Related InvestmentsProgramRelated
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Intangible Assets IntangibleAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Other Assets Total OtherAssetsTotal
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 33844 | BOY |
| EOY | 1465 | EOY |
Total Assets TotalAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 9909027 | BOY |
| EOY | 8117853 | EOY |
Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1854443 | BOY |
| EOY | 1994217 | EOY |
Grants Payable GrantsPayable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Deferred Revenue DeferredRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 443413 | BOY |
| EOY | 377033 | EOY |
Tax Exempt Bond Liabilities TaxExemptBondLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Escrow Account Liability EscrowAccountLiability
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Loans From Officers Directors LoansFromOfficersDirectors
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Other Liabilities OtherLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 0 | BOY |
| EOY | 0 | EOY |
Total Liabilities TotalLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 2297856 | BOY |
| EOY | 2371250 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Follow SFAS117 | X | FollowSFAS117 |
Unrestricted Net Assets UnrestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -872677 | BOY |
| EOY | -1768266 | EOY |
Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 8421755 | BOY |
| EOY | 7452776 | EOY |
Permanently Restricted Net Assets PermanentlyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 62093 | BOY |
| EOY | 62093 | EOY |
Total Net Assets Fund Balances TotalNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 7611171 | BOY |
| EOY | 5746603 | EOY |
Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 9909027 | BOY |
| EOY | 8117853 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expenses | -1864568 | ReconcilationRevenueExpenses |
| Method Of Accounting Accrual | X | MethodOfAccountingAccrual |
| Accountant Compile Or Review | false | AccountantCompileOrReview |
| FS Audited | true | FSAudited |
| Audit Committee | true | AuditCommittee |
| Financial Statement Consolidated | X | FinancialStatementConsolidated |
| Federal Grant Audit Required | false | FederalGrantAuditRequired |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Publicly Supported Org170b1 Avi | X | PubliclySupportedOrg170b1Avi |
Gifts Grants Contrib Received170 GiftsGrantsContribReceived170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 5598863 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 4359865 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 721605 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 5945925 | CurrentTaxYearMinus1Year |
| Current Tax Year | 5860920 | CurrentTaxYear |
| Total | 22487178 | Total |
Total170 Total170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 5598863 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 4359865 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 721605 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 5945925 | CurrentTaxYearMinus1Year |
| Current Tax Year | 5860920 | CurrentTaxYear |
| Total | 22487178 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Amounts Subst Contributors Total | 5348602 | AmountsSubstContributorsTotal |
| Public Support Total170 | 17138576 | PublicSupportTotal170 |
Gross Investment Income170 GrossInvestmentIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 188867 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 74077 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 33934 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 152708 | CurrentTaxYearMinus1Year |
| Current Tax Year | 20879 | CurrentTaxYear |
| Total | 470465 | Total |
Other Income170 OtherIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus1 Year | 2334 | CurrentTaxYearMinus1Year |
| Current Tax Year | 433 | CurrentTaxYear |
| Total | 2767 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | 22960410 | TotalSupport |
| Public Support Pertcentage170 | 0.74644 | PublicSupportPertcentage170 |
| Public Support Pertcent Prior Year | 0.70108 | PublicSupportPertcentPriorYear |
| Thirty Three Percnt Tests CY170 | X | ThirtyThreePercntTestsCY170 |
Schedule B IRS990ScheduleB
Contributor Info ContributorInfo
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor Number | RESTRICTED | ContributorNumber |
Contributor Name Business ContributorNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor Address US ContributorAddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Aggregate Contributions | RESTRICTED | AggregateContributions |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Art Public Exhibition Amts | ArtPublicExhibitionAmts | |
| Held Works Of Art Amts | HeldWorksOfArtAmts |
Current Year CurrentYear
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 62093 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 6787 | InvestmentEarningsOrLosses |
| Other Expenditures | 6787 | OtherExpenditures |
| End Of Year Balance | 62093 | EndOfYearBalance |
Current Year Minus1 Year CurrentYearMinus1Year
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 62093 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 6025 | InvestmentEarningsOrLosses |
| Other Expenditures | 6025 | OtherExpenditures |
| End Of Year Balance | 62093 | EndOfYearBalance |
Current Year Minus2 Years CurrentYearMinus2Years
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 62093 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 7353 | InvestmentEarningsOrLosses |
| Other Expenditures | 7353 | OtherExpenditures |
| End Of Year Balance | 62093 | EndOfYearBalance |
Current Year Minus3 Years CurrentYearMinus3Years
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 62093 | BeginningOfYearBalance |
| Investment Earnings Or Losses | 6606 | InvestmentEarningsOrLosses |
| Other Expenditures | 6606 | OtherExpenditures |
| End Of Year Balance | 62093 | EndOfYearBalance |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated EOY Balance | 0.00000 | BoardDesignatedEOYBalance |
| Permanent Endowment EOY Balance | 1.00000 | PermanentEndowmentEOYBalance |
| Term Endowment EOY Balance | 0.00000 | TermEndowmentEOYBalance |
| Endowments Held By Unrelated Orgs | false | EndowmentsHeldByUnrelatedOrgs |
| Endowments Held By Related Orgs | true | EndowmentsHeldByRelatedOrgs |
| Are Related Orgs Listed Schedule R | true | AreRelatedOrgsListedScheduleR |
| Land | Land | |
| Buildings | Buildings |
Leasehold Improvements LeaseholdImprovements
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 11053 | OtherCostOrOtherBasis |
| Depreciation | 11053 | Depreciation |
| Book Value | 0 | BookValue |
Equipment Equipment
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 157116 | OtherCostOrOtherBasis |
| Depreciation | 156210 | Depreciation |
| Book Value | 906 | BookValue |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Land Buildings | OtherLandBuildings | |
| Total Of Book Value Land Buildings | 906 | TotalOfBookValueLandBuildings |
| Federal Income Tax Liability | 0 | FederalIncomeTaxLiability |
| Total Of Amounts | 0 | TotalOfAmounts |
Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| ENDOWMENTS | SCHEDULE D, PART V | THE INSTITUTE'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR THE NEXT 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. THE INSTITUTE CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES. |
| ASC 740 (FIN 48) FOOTNOTE | SCHEDULE D, PART X | MANAGEMENT IS OF THE OPINION THAT SUBSTANTIALLY ALL OF TGEN'S AND THE FOUNDATION'S ACTIVITIES ARE RELATED TO THEIR EXEMPT PURPOSES, AND NO MATERIAL UNCERTAIN TAX POSITIONS HAVE BEEN IDENTIFIED OR RECORDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS AT DECEMBER 31, 2012. TGEN AND THE FOUNDATION FILE FORMS 990 IN THE U.S. FEDERAL JURISDICTION AND COMPARABLE FORMS IN THE STATE OF ARIZONA. TAX FILINGS FOR 2008 THROUGH 2011 ARE SUBJECT TO EXAMINATION; HOWEVER, THE INSTITUTE HAS NOT BEEN NOTIFIED OF ANY SUCH EXAMINATIONS. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Records Maintained | true | RecordsMaintained |
Recipient Table RecipientTable
Recipient Name Business RecipientNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | BusinessNameLine1 |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 445 N 5TH STREET STE 600 | AddressLine1 |
| City | PHOENIX | City |
| State | AZ | State |
| ZIP Code | 85004 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN Of Recipient | 753065445 | EINOfRecipient |
| IRC Section | 501(C)(3) | IRCSection |
| Amount Of Cash Grant | 6322898 | AmountOfCashGrant |
| Amount Of Non Cash Assistance | 0 | AmountOfNonCashAssistance |
| Method Of Valuation | N/A | MethodOfValuation |
| Description Of Non Cash Assistance | N/A | DescriptionOfNonCashAssistance |
| Purpose Of Grant | FUNDRAISING FOR TGEN | PurposeOfGrant |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Nbr Of501 C3 And Govt Grants | 1 | TotalNbrOf501C3AndGovtGrants |
| Total Nbr Of Other Organizations | 0 | TotalNbrOfOtherOrganizations |
Form990 Schedule I Part IV Form990ScheduleIPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | PROCESS FOR MONITORING USE OF GRANT FUNDS IN THE U.S. | Identifier |
| Return Reference | SCHEDULE I, PART I, LINE 2 | ReturnReference |
| Explanation | THE FOUNDATION IS ORGANIZED EXCLUSIVELY TO BENEFIT TGEN, A RELATED 501(C)(3) TAX-EXEMPT ORGANIZATION, BY SUPPORTING TGEN'S FUNDRAISING AND DEVELOPMENT FUNCTIONS. | Explanation |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | X | FirstClassOrCharterTravel |
| Written Policy Re T And E Expenses | true | WrittenPolicyReTAndEExpenses |
| Substantiation Required | true | SubstantiationRequired |
| Severance Payment | false | SeverancePayment |
| Supplemental Nonqual Retire Plan | false | SupplementalNonqualRetirePlan |
| Equity Based Comp Arrangement | false | EquityBasedCompArrangement |
| Comp Based On Revenue Of Filing Org | false | CompBasedOnRevenueOfFilingOrg |
| Comp Based On Revenue Related Orgs | false | CompBasedOnRevenueRelatedOrgs |
| Comp Based Net Earnings Filing Org | false | CompBasedNetEarningsFilingOrg |
| Comp Based Net Earnings Relate Orgs | false | CompBasedNetEarningsRelateOrgs |
| Any Non Fixed Payments | true | AnyNonFixedPayments |
| Initial Contract Exception | false | InitialContractException |
Form990 Schedule J Part II Form990ScheduleJPartII (5 entries)
| Base Compensation Filing OrgBaseCompensationFilingOrg | Comp Based On Related OrgsCompBasedOnRelatedOrgs | Bonus Filing OrgBonusFilingOrg | Bonus Related OrgsBonusRelatedOrgs | Other Compensation Filing OrgOtherCompensationFilingOrg | Other Compensation Related OrgsOtherCompensationRelatedOrgs | Deferred Comp Filing OrgDeferredCompFilingOrg | Deferred Comp Related OrgsDeferredCompRelatedOrgs | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg | Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs | Total Compensation Filing OrgTotalCompensationFilingOrg | Total Compensation Related OrgsTotalCompensationRelatedOrgs | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg | Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MICHAEL BASSOFF | |||||||||||||
| 0 | 414595 | 0 | 0 | 0 | 18135 | 0 | 9800 | 0 | 8558 | 0 | 451088 | 0 | 0 |
| DENISE MCCLINTIC THRU 122011 | |||||||||||||
| 0 | 158301 | 0 | 0 | 0 | 1806 | 0 | 1744 | 0 | 4937 | 0 | 166788 | 0 | 0 |
| TERESA BURLESON | |||||||||||||
| 0 | 381110 | 0 | 57830 | 0 | 1782 | 0 | 9744 | 0 | 6315 | 0 | 456781 | 0 | 0 |
| JEFFREY M TRENT PHD | |||||||||||||
| 0 | 990045 | 0 | 0 | 0 | 95347 | 0 | 454039 | 0 | 1440 | 0 | 1540871 | 0 | 0 |
| Elizabeth Montemayor | |||||||||||||
| 0 | 219291 | 0 | 22821 | 0 | 2101 | 0 | 9756 | 0 | 10594 | 0 | 264563 | 0 | 0 |
Form990 Schedule J Part III Form990ScheduleJPartIII (4 entries)
| IdentifierIdentifier | ExplanationExplanation |
|---|---|
| SCHEDULE J, PART I, LINE 1A | FIRST CLASS TRAVEL IS PERMITTED BY EXECUTIVE STAFF ONLY AND MUST, PER TGEN POLICY, BE PRE-APPROVED BY THE CHIEF OPERATING OFFICER. THESE EXPENSES WERE NOT CONSIDERED AS TAXABLE COMPENSATION TO THE RECIPIENT SINCE THEY WERE REIMBURSEMENTS FOR BUSINESS USE UNDER AN ACCOUNTABLE PLAN. |
| SCHEDULE J, PART I, LINE 7 | SOME OF THE PERSONS LISTED IN FORM 990, PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE BASES. |
| SCHEDULE J, PART II | DR. TRENT IS PAID BY VARI, A RELATED TAX-EXEMPT ORGANIZATION. A PORTION OF HIS SALARY IS THEN REIMBURSED BY TGEN FOR SERVICES RENDERED TO TGEN. |
| SCHEDULE J, PART II, COL C | A RETENTION AGREEMENT WITH DR. TRENT PROVIDES FOR $500,000 TO BE PAID BY TGEN ON MARCH 12, 2017. THE PORTION OF THE BONUS THAT WAS ACCRUED BY TGEN THIS YEAR ($211,539) IS REPORTED AS DEFERRED COMPENSATION IN PART II. IN ADDITION, $242,500 IS BEING REPORTED BY VAN ANDEL RESEARCH INSTITUTE AS DEFERRED COMPENSATION. |
Schedule O IRS990ScheduleO
General Explanation GeneralExplanation (13 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| DESCRIPTION OF PROGRAM SERVICE ACCOMPLISHMENTS | FORM 990, PART III, LINE 4 | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION RAISES FUNDS FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE ("TGEN"). THE PROGRAM SERVICE ACCOMPLISHMENTS OF TGEN ARE LISTED BELOW: INTRODUCTION TGEN CELEBRATED ITS 10TH ANNIVERSARY IN 2012. IT WAS IN FEBRUARY 2002 THAT AN ASSEMBLY OF MORE THAN 50 ARIZONA LEADERS AND VISIONARIES IN SCIENCE, MEDICINE, GOVERNMENT AND BUSINESS GATHERED AT THE ARIZONA STATE CAPITOL TO DISCUSS THE POSSIBILITY OF ESTABLISHING ARIZONA AS A SIGNIFICANT PLAYER IN THE NEW KNOWLEDGE-BASED ECONOMY OF THE BIOMEDICAL-BIOTECHNOLOGY INDUSTRY. AS TGEN ENTERS ITS SECOND DECADE, THE INSTITUTE CONTINUES TO DEFINE ITSELF BY EMPHASIZING WHAT WE CAN DO FOR PATIENTS TODAY. THE PROSPECTS FOR INCREASINGLY SIGNIFICANT LABORATORY DISCOVERIES AND OUR TRANSLATION OF THAT NEW SCIENCE INTO CLINICAL BENEFITS FOR PATIENTS WHO HAVE NO TIME TO WAIT HEIGHTEN OUR SENSE OF URGENCY. A NUMBER OF OUR MOST RECENT COLLABORATIONS POINT TO THIS EXCITING NEW ERA OF GENOMIC MEDICINE. THESE INCLUDE: - A MULTI-YEAR, MULTI-MILLION-DOLLAR CONTRACT WITH THE MULTIPLE MYELOMA RESEARCH FOUNDATION TO TRACK CHANGES IN THE GENOMES (DNA) OF AN UNPRECEDENTED 1,000-PATIENT NATIONAL STUDY OF THIS BONE MARROW CANCER. - OUR CLINICAL TRIALS PROGRAM, IN PARTNERSHIP WITH SCOTTSDALE HEALTHCARE AND BIND BIOSCIENCES, SHOWED THE SUCCESSFUL FIRST USE OF NANOPARTICLES, MICROSCOPIC DRONES, TO DELIVER TARGETED MEDICINES, SHRINKING AND EVEN ELIMINATING PATIENTS' TUMORS, ACCORDING TO A STUDY REPORTED IN THE JOURNAL SCIENCE TRANSLATIONAL MEDICINE AND PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). - AS REPORTED IN THE NEW ENGLAND JOURNAL OF MEDICINE, TGEN AND ITS COLLABORATORS IDENTIFIED THE FIRST MAJOR GENE MUTATION ASSOCIATED WITH HEREDITARY PROSTATE CANCER, FOLLOWING A 20-YEAR QUEST TO DISCOVER A GENETIC DRIVER FOR THIS DISEASE. - IN FEBRUARY, VISMODEGIB BECAME THE FIRST DRUG TESTED AT TGEN'S CLINIC TRIALS PROGRAM TO RECEIVE FDA APPROVAL. THIS ALSO WAS THE FIRST DRUG APPROVED BY THE FDA TO TREAT INOPERABLE BASAL CELL CARCINOMA, A TYPE OF SKIN CANCER PREVALENT IN ARIZONA. IN ADDITION, WE ANTICIPATE CONTINUING AND STRONGER COLLABORATIONS WITH ALL OUR MAJOR PARTNERS, SIGNIFICANT NEW OPPORTUNITIES WITH BIOTECH AND BIOPHARMA INDUSTRIES, AND AN ACCELERATION OF PROGRESS IN THE AREA OF COMMERCIALIZATION. TGEN'S NEW CLIA (CLINICAL LABORATORY IMPROVEMENT AMENDMENTS) LABORATORY -NAMED THE DORRANCE CLINICAL LABORATORY- ON THE 4TH FLOOR OF OUR HEADQUARTERS BUILDING ENHANCES MANY OF THESE INITIATIVE BY STREAMLINING OUR ABILITY TO PROVIDE ONCOLOGISTS WITH TIMELY GENOMIC ANALYSIS AND ACCELERATE PATIENT BENEFIT. THIS MEANS TGEN NO LONGER NEEDS TO VALIDATE ITS GENOMIC FINDINGS THROUGH AN OUTSIDE CLIA LAB BEFORE SHARING THE RESULTS WITH ONCOLOGISTS AND THEIR PATIENTS. CHIEF AMONG THESE IS THE ANNOUNCEMENT IN JULY OF $10 MILLION IN GRANTS FROM THE BEN & CATHERINE IVY FOUNDATION TO FUND TWO MULTI-YEAR PROJECTS THAT AIM TO DISCOVER THE GENOMIC ORIGINS OF GLIOBLASTOMA, A BRAIN CANCER WITH FEW TREATMENT OPTIONS FOR PATIENTS. AS PART OF THESE PROJECTS, CLINICAL TRIALS WILL TEAM US WITH SOME OF THE NATION'S MORE ESTABLISHED RESEARCH CENTERS, INCLUDING MEMORIAL SLOAN KETTERING CANCER CENTER, AND THE DANA-FARBER/HARVARD CANCER CENTER. IN EARLY OCTOBER, TGEN ANNOUNCED THE FORMATION OF THE TGEN CENTER FOR RARE CHILDHOOD DISORDERS -DUBBED C4RCD. THIS NEW CENTER CREATES A FOCAL POINT - FOR THE PUBLIC, OUR PARTNERS, AND MOST IMPORTANTLY OUR PATIENTS AND THEIR FAMILIES - WHERE WE CAN BEGIN TO UNLOCK THE MYSTERIES BEHIND THE DISEASES AND CONDITIONS, MANY OF THEM UNNAMED, WHICH FOR TOO LONG HAVE BEEN INSUFFICIENTLY ADDRESSED. WHILE MANY OF THESE CONDITIONS AFFECT ONLY A FEW CHILDREN, COLLECTIVELY THEY ACCOUNT FOR THOUSANDS OF CHILDREN IN ARIZONA AND ACROSS THE NATION. IN NOVEMBER, TGEN LAUNCHED THE KIRSTEN'S LEGACY WEBSITE, IN MEMORY OF PATIENT AND TGEN ADVOCATE KIRSTEN SANDSTROM. THE WEBSITE PROVIDES PATIENTS AND THEIR FAMILIES WITH 24-7 ACCESS TO ESSENTIAL AND COMPREHENSIVE INFORMATION ON ADRENOCORTICAL CARCINOMA (ACC), A RARE AND DEADLY FORM OF CANCER. KIRSTEN'S LEGACY IS TGEN'S RESEARCH AND CLINICAL PROGRAM FOR DEFEATING ACC, PROVIDING VALUABLE PATIENT RESOURCES AND THE LATEST UPDATES ON PROGRESS MADE BY TGEN RESEARCHERS AND CLINICIANS. THE WEBSITE AND ACTIVITIES SURROUNDING IT BUILD ON THE FOUNDING ACC EFFORTS OF TROY RICHARDS, WHOSE EFFORTS ENABLED TGEN TO ESTABLISH A NATIONAL RESEARCH-FUND INITIATIVE FOR THIS RARE BUT DEADLY DISEASE. THESE AND OTHER PROJECTS WILL TAKE FULL ADVANTAGE OF TGEN'S RECOGNIZED EXPERTISE IN GENOMIC RESEARCH, AND WILL ONLY STRENGTHEN TIES WITH OUR MANY COLLABORATORS IN ARIZONA, ACROSS THE NATION, AND AROUND THE WORLD, HELPING ENABLE ARIZONA'S BIOMEDICAL INDUSTRY TO CONTINUE ITS POSITIVE GROWTH. IN ADDITION, THE FOLLOWING OVERVIEW PROVIDES A SNAPSHOT OF RECENT PROGRESS IN SCIENTIFIC PUBLICATIONS, GRANTS, CONTRACTS, PHILANTHROPY, EDUCATION AND OUTREACH, MEDIA AND COMMUNITY RECOGNITION. |
| PEER-REVIEWED LABORATORY RESEARCH PUBLICATIONS AND PRESENTATIONS | SINCE ITS INCEPTION, TGEN'S BIOMEDICAL RESEARCH HAS FOCUSED ON THE PATIENT AS AN END POINT. TGEN FACULTY WORK TO DISCOVER THE UNDERLYING CAUSE OF DISEASE PROGRESSION AND RESISTANCE TO THERAPY AND WHY SOME INDIVIDUALS ENCOUNTER DEBILITATING DISEASES AND OTHERS LIVE HEALTHY LIVES. DRIVEN BY THE LATEST TECHNOLOGY, TGEN EFFORTS REMAIN EQUAL TO THE STRENGTHS AND CAPABILITIES OF ANY OF TODAY'S LEADING RESEARCH AND CLINICAL INSTITUTES. NOWHERE IS THIS MORE EVIDENT THAN WITH TGEN'S WHOLE GENOME SEQUENCING CAPABILITIES. WHOLE GENOME SEQUENCING ALLOWS US TO DIG DEEPER INTO THE GENOME THAN EVER BEFORE BY PROVIDING MORE INFORMATION AND INCREASING OUR PROBABILITY OF IDENTIFYING SOMETHING SIGNIFICANT. THE LONG-TERM HOPE IS THAT DOCTORS WILL LEVERAGE THIS INFORMATION TO INFORM DECISIONS ABOUT PATIENT CARE. THE RESULTS FROM THESE RESEARCH STUDIES APPEAR IN A NUMBER OF LEADING SCIENTIFIC AND MEDICAL JOURNALS, AND ADD TO THE GROWING KNOWLEDGE BASE OF MOLECULAR RESEARCH AND MEDICINE. IN 2012, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS NEW ENGLAND JOURNAL OF MEDICINE, PROSTATE, PLOS, BLOOD, JOURNAL OF CANCER, JOURNAL OF CLINICAL ONCOLOGY, AND A HOST OF OTHER DISEASE-ASSOCIATED PUBLICATIONS. SELECT HIGHLIGHTS FOR FY12 1. IN A STUDY OF 144 PATIENTS WITH ADVANCED CANCER, INCLUDING COLORECTAL, OTHER GASTROINTESTINAL AND PROSTATE CANCERS, RESEARCHERS AT TGEN AND SCOTTSDALE HEALTHCARE DOCUMENTED A STATISTICALLY SIGNIFICANT DECREASE IN PROGRESSION-FREE SURVIVAL WITH EACH SUCCESSIVE STANDARD THERAPY. THE STUDY PUBLISHED NOV. 28 IN THE JOURNAL OF CANCER CONCLUDED THAT NEW THERAPIES THAT REVERSE THIS TREND MIGHT LEAD TO IMPROVED CLINICAL OUTCOMES. CITATION: "PROGRESSION-FREE SURVIVAL DECREASES WITH EACH SUBSEQUENT THERAPY IN PATIENTS PRESENTING FOR PHASE I CLINICAL TRIALS." CHRISTOPHER H. BAILEY, GAYLE JAMESON, CHAO SIMA, SHARON FLECK, ERICA WHITE, DANIEL D. VON HOFF, GLEN J. WEISS. J CANCER 2012; 3:7-13. 2. A TGEN STUDY PUBLISHED NOV. 22 IN THE JOURNAL LUNG CANCER SHOWED THAT KEY DOWNSTREAM COMPONENTS OF THE HEDGEHOG SIGNALING PATHWAY (HHSP), WHICH HAS BEEN IMPLICATED IN THE DEVELOPMENT OF MULTIPLE CANCERS, SHOW CORRELATION WITH SONIC HEDGEHOG LIGAND (SHH) EXPRESSION, SUGGESTING THAT LIGAND-DEPENDENT SIGNALING IS MORE PREVALENT IN PRIMARY NON-SMALL CELL LUNG CANCER TUMORS. CITATION: RAZ G, ALLEN KE, KINGSLEY C, CHERNI I, ARORA S, WATANABE A, LORENZO CD, EDWARDS V DK, SRIDHAR S, HOSTETTER G, WEISS GJ. "HEDGEHOG SIGNALING PATHWAY MOLECULES AND ALDH1A1 EXPRESSION IN EARLY-STAGE NON-SMALL CELL LUNG CANCER." DOI:10.1016/J.LUNGCAN.2011.10.015. 3. AN ABSTRACT PREPARED BY TGEN AND OTHERS AND PRESENTED IN DECEMBER AT THE 2011 CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM SHOWED THE VALUE OF WHOLE-GENOME SEQUENCING. RESEARCHERS AT TGEN COLLABORATED WITH US ONCOLOGY, LIFE TECHNOLOGIES AND BAYLOR'S CHARLES A. SAMMONS CANCER CENTER AND FOUND AN IMPRESSIVE RESPONSE TO AN INHIBITOR OF THE MEK/AKT CELLULAR PATHWAY IN TRIPLE-NEGATIVE BREAST CANCER. CITATION: JOYCE A. O'SHAUGHNESSY, DAVID W. CRAIG, JEFFREY KIEFER, SHRIPAD SINARI, TRACY M. MOSES, SHUKMEI WONG, JESSICA ALDRICH, ALEXIS CHRISTOFORIDES, JENNIFER DINH, TYLER ITZATT, JOANNE BLUM, AHMET KURDOGLU, BODOUR SALHIA, ANGELA BAKER, ASIM SIDDIQUI, LINH HOANG, PAUL BILLINGS, JEFFREY M. TRENT, SPYRO MOUSSES, DANIEL VON HOFF, JOHN D. CARPTEN. ABSTRACT TITLE: "NEXT GENERATION SEQUENCING REVEALS CO-ACTIVATING EVENTS IN THE MAPK AND PI3K/AKT PATHWAYS IN METASTATIC TRIPLE NEGATIVE BREAST CANCERS." 4. IN A STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE, THE HOXB13 G84E VARIANT IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF HEREDITARY PROSTATE CANCER. ALTHOUGH THE VARIANT ACCOUNTS FOR A SMALL FRACTION OF ALL PROSTATE CANCERS, THIS FINDING HAS IMPLICATIONS FOR PROSTATE-CANCER RISK ASSESSMENT AND MAY PROVIDE NEW MECHANISTIC INSIGHTS INTO THIS COMMON CANCER. CITATION: "GERMLINE MUTATIONS IN HOXB13 AND PROSTATE-CANCER RISK." CHARLES M. EWING, M.S., ANNA M. RAY, M.S., ETHAN M. LANGE, PH.D., KIMBERLY A. ZUHLKE, B.A., CHRISTIANE M. ROBBINS, M.S., WAIBHAV D. TEMBE, PH.D., KATHLEEN E. WILEY, M.S., SARAH D. ISAACS, M.S., DORHYUN JOHNG, B.A., YUNFEI WANG, M.S., CHRIS BIZON, PH.D., GUIFANG YAN, B.S., MARTA GIELZAK, B.A., ALAN W. PARTIN, M.D., PH.D., VIJAYALAKSHMI SHANMUGAM, PH.D., TYLER IZATT, M.S., SHRIPAD SINARI, M.S., DAVID W. CRAIG, PH.D., S. LILLY ZHENG, M.D., PATRICK C. WALSH, M.D., JAMES E. MONTIE, M.D., JIANFENG XU, M.D., DR.P.H., JOHN D. CARPTEN, PH.D., WILLIAM B. ISAACS, PH.D., AND KATHLEEN A. COONEY, M.D. N ENGL J MED 2012; 366:141-149 JAN, 2012. | |
| 5. WHOLE GENOME SEQUENCING OF A RARE NASAL TRACT CANCER CALLED OLFACTORY | NEUROBLASTOMA IDENTIFIED GENETIC MUTATIONS THAT COULD BE FUTURE TARGETS OF ADVANCED PRECISION-MEDICINE DRUG DEVELOPMENT, ACCORDING TO A STUDY PUBLISHED IN THE JOURNAL PLOS ONE. A COMPARISON OF A PATIENT'S NORMAL AND TUMOR DNA IDENTIFIED SIGNIFICANT GENE MUTATIONS, SELECTED BASED ON CLINICAL RELEVANCE OF THE TARGET GENES AND THEIR ASSOCIATION WITH THE PROGRESSION OF CANCER. CITATION: WEISS GJ, LIANG WS, IZATT T, ARORA S, CHERNI I, ET AL. (2012). "PAIRED TUMOR AND NORMAL WHOLE GENOME SEQUENCING OF METASTATIC OLFACTORY NEUROBLASTOMA." PLOS ONE 7(5): E37029. DOI:10.1371/JOURNAL.PONE.0037029. 6. IN A SCAN OF 1,233 PROSTATE CANCER FAMILIES, RESEARCHERS IDENTIFIED SUGGESTIVE EVIDENCE FOR LINKAGE IN CHROMOSOMES 4 AND 8, WITH ADDITIONAL REGIONS IMPLICATED IN SUBSETS OF FAMILIES DEFINED BY AGE AT DIAGNOSIS, DISEASE AGGRESSIVENESS, OR NUMBER OF AFFECTED MEMBERS. THESE RESULTS, PUBLISHED IN THE MARCH ISSUE OF THE JOURNAL PROSTATE, WILL BE USEFUL IN PRIORITIZING FUTURE SUSCEPTIBILITY GENE DISCOVERY EFFORTS IN THIS COMMON CANCER. CITATION: "CHROMOSOMES 4 AND 8 IMPLICATED IN A GENOME WIDE SNP LINKAGE SCAN OF 762 PROSTATE CANCER FAMILIES COLLECTED BY THE ICPCG." JOHN CARPTEN AND 37 COLLABORATORS, INCLUDING THE INTERNATIONAL CONSORTIUM FOR PROSTATE CANCER GENETICS. PROSTATE. 2012 MAR;72(4):410-26. DOI: 10.1002/PROS.21443. 7. IN A STUDY OF HOW BRAIN CANCER CELLS SPREAD, RESEARCHERS FOUND THAT THE CDC42 GENES AND THE PROTEINS ECT2 AND TRIO HAVE AN EFFECT ON HOW THE TWEAK-FN14 SIGNALING PATHWAY STIMULATES THE MIGRATION AND INVASION OF GLIOMA CELLS. THESE FINDINGS, PUBLISHED IN MAY IN THE JOURNAL MOLECULAR CANCER RESEARCH, PROVIDE A POTENTIAL INNOVATIVE DRUG TARGET FOR GLIOMA THERAPY. CITATION: "CDC42 AND THE GUANINE NUCLEOTIDE EXCHANGE FACTORS ECT2 AND TRIO MEDIATE FN14-RAC1-INDUCED MIGRATION AND INVASION OF GLIOBLASTOMA CELLS." SHANNON FORTIN, NHAN TRAN AND 8 OTHER COLLABORATORS. MOL CANCER RES. 2012 JUL;10(7):958-68. EPUB 2012 MAY 9. 8. FOLLOWING UP ON A 2009 OUTBREAK OF ANTHRAX AMONG HEROIN USERS IN SCOTLAND, THIS STUDY USED WHOLE GENOME SEQUENCING TO DISCOVER THAT A NEW OUTBREAK OF ANTHRAX IN SCOTLAND, ENGLAND AND GERMANY WAS LINKED TO TURKEY, AND NOT TO PREVIOUS ISOLATES FROM SCOTLAND OR AFGHANISTAN. CITATION: PRICE EP, SEYMOUR ML, SAROVICH DS, LATHAM J, WOLKEN SR, MASON J, ET AL. "MOLECULAR EPIDEMIOLOGIC INVESTIGATION OF AN ANTHRAX OUTBREAK AMONG HEROIN USERS, EUROPE." EMERG INFECT DIS. 2012 AUG DOI: 10.3201/EID1808.111343. 9. WHOLE GENOME SEQUENCING WAS USED FOR THE FIRST TIME TO SIMULTANEOUSLY PROFILE THREE PATIENTS WITH PANCREATIC CANCER IN THIS TGEN-LED STUDY PUBLISHED IN OCTOBER BY PLOS ONE. THE ANALYSIS, ASSISTED BY SCOTTSDALE HEALTHCARE AND MAYO CLINIC, SHOWED THAT WGS "IS AN OBVIOUS AND POWERFUL METHOD FOR ADVANCING OUR UNDERSTANDING OF PANCREATIC CANCER." IN ALL THREE CASE STUDIES, THE REPORT FOUND MULTIPLE POTENTIAL THERAPEUTIC TARGETS, HIGHLIGHTING THE NEED TO STUDY THE FULL SPECTRUM OF THE GENOME AND RE-EMPHASIZING THE NEED TO DEVELOP MULTIPLE AVENUES OF THERAPEUTICS TO MATCH THE SPECIFIC MEDICAL CHALLENGES OF EACH PATIENT. CITATION: "GENOME-WIDE CHARACTERIZATION OF PANCREATIC ADENOCARCINOMA PATIENTS USING NEXT GENERATION SEQUENCING." LIANG WS, CRAIG DW, CARPTEN J, BORAD MJ, DEMEURE MJ, ET AL. (2012) GENOME-WIDE CHARACTERIZATION OF PANCREATIC ADENOCARCINOMA PATIENTS USING NEXT GENERATION SEQUENCING. PLOS ONE 7(10): E43192. DOI:10.1371/JOURNAL.PONE.0043192 10. IN ANOTHER EFFORT TO DISCOVER BETTER THERAPIES FOR PANCREATIC CANCER, THIS STUDY PUBLISHED IN 2012 IN THE JOURNAL OF CLINICAL ONCOLOGY SCANNED THE RECORDS OF MORE THAN 1,000 PATIENTS, RESULTING IN THE IDENTIFICATION OF NUMEROUS ACTIONABLE TARGETS FOR FURTHER RESEARCH. THE STUDY REITERATED THE IMPORTANCE OF KRAS MUTATIONS, SUGGESTED TOPO2 INHIBITORS FOR EXAMINATION, AND ENCOURAGED THE POSSIBLE EXPLORATION OF OTHER CELLULAR PATHWAYS, INCLUDING DNA REPAIR AND AMINO ACID TARGETS. THIS STUDY WAS SUPPORTED IN PART BY A STAND UP TO CANCER DREAM TEAM AWARD. CITATION: "ACTIONABLE TARGETS IN PANCREATIC CANCER DETECTED BY IMMUNOHISTOCHEMISTRY (IHC), MICROARRAY (MA) FLUORESCENT IN SITU HYBRIDIZATION (FISH), AND MUTATIONAL ANALYSIS." DANIEL D. VON HOFF, RAMESH K. RAMANATHAN, DOUGLAS B. EVANS, MICHAEL J. DEMEURE, TODD MANEY, BRIAN WRIGHT, ZORAN GATALICA, MATTHEW JEROME MCGINNISS; VIRGINIA G. PIPER CANCER CENTER AT SCOTTSDALE HEALTHCARE/TGEN, SCOTTSDALE, AZ; MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI; TRANSLATIONAL GENOMIC RESEARCH INSTITUTE, PHOENIX, AZ; CARIS LIFE SCIENCES, PHOENIX, AZ. J CLIN ONCOL 30, 2012 (SUPPL; ABSTR 4013) | |
| CLINICAL RESEARCH / CLINICAL TRIALS | MEDICINE IS AT A CROSSROADS. GENOMIC AND OTHER -OMIC GENERATED INFORMATION CAN GREATLY INFORM THERAPEUTIC DECISIONS BY PROVIDING A GREATER UNDERSTANDING OF THE UNDERLYING BIOLOGICAL DEFECTS ASSOCIATED WITH A PARTICULAR DISEASE OR DISORDER. SINCE DAY ONE AT TGEN, OUR GOAL HAS ALWAYS BEEN TO CHAMPION GENOMIC-BASED MEDICINE BY USING AN INDIVIDUAL'S GENETIC PROFILE TO GUIDE CLINICAL DECISIONS ABOUT PREVENTING, DIAGNOSING, AND TREATING HIS OR HER DISEASE. MATCHING THE RIGHT PATIENT WITH THE RIGHT THERAPY APPROPRIATE TO THE UNDERLYING GENETICS OF THEIR SPECIFIC DISEASE WILL MEAN THAT A HIGHER PROPORTION OF PATIENTS WILL BENEFIT. THERE WILL BE MORE DURABLE RESPONSES AND LONGER SURVIVAL TIMES. THERE WILL BE LESS UNNECESSARY TOXICITY, EXPENSE, AND TIME WASTED ON INEFFECTIVE THERAPIES. ESTABLISHED IN 2006, THE VIRGINIA G. PIPER CANCER CENTER (VGPCC) CLINICAL TRIALS PROGRAM AT SCOTTSDALE HEALTHCARE, A STRATEGIC ALLIANCE WITH SCOTTSDALE HEALTHCARE (SHC), PROVIDES A DIRECT CLINICAL RESEARCH SITE FOR TGEN. DR. DANIEL VON HOFF, TGEN'S PHYSICIAN-IN-CHIEF, SERVES AS CHIEF SCIENTIFIC OFFICER. PROGRAM CLINICIANS FOCUS ON CLINICAL TRIALS WITH TARGETED AGENTS AND GENOMICS-BASED INDIVIDUALIZED THERAPY. THE VGPCC CLINICAL TRIALS PROGRAM, WITH AN INITIAL FOCUS ON CANCER, ALLOWS THE UNIQUE OPPORTUNITY FOR TGEN TO TRANSITION ITS LABORATORY-BASED RESEARCH TO PATIENT CARE CENTERED ON INDIVIDUALIZED THERAPY. PROGRAM STAFF CURRENTLY WORKING ON THE PHASE I CLINICAL TRIALS PATIENT PARTICIPATION IN CLINICAL TRIALS INCLUDE: - OVER 300 VISITS PER MONTH - NEARLY 40 NEW PATIENTS PER MONTH - OVER 400 PATIENT SAMPLES COLLECTED PER MONTH. 2012 HIGHLIGHTS FEBRUARY 1, 2012 - A NEW SKIN CANCER DRUG TESTED FOR THE FIRST TIME IN THE WORLD FIVE YEARS EARLIER BY TGEN AND SCOTTSDALE HEALTHCARE RECEIVES EXPEDITED APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION, A REMARKABLE ACCOMPLISHMENT IN NEW DRUG DEVELOPMENT. APRIL 3, 2012 - RESULTS OF THE FEASIBILITY OF SELECTING TREATMENT BASED ON INDIVIDUAL MOLECULAR CHARACTERISTICS WAS DEMONSTRATED IN A FIRST-OF-ITS KIND PANCREATIC CANCER CLINICAL TRIAL WAS REPORTED BY TGEN / SCOTTSDALE HEALTHCARE AT AACR ANNUAL MEETING. JUNE 13, 2012 - TGEN / SCOTTSDALE HEALTHCARE STUDY AN INVESTIGATIONAL DRUG THAT ACTS LIKE A TROJAN HORSE TO DELIVER CANCER KILLING AGENTS FOR PANCREATIC. THE PHASE 2 CLINICAL TRIAL TESTS THE EFFECTIVENESS AND SAFETY OF INNO-206 IN PATIENTS WITH ADVANCED PANCREATIC DUCTUAL ADENOCARCINOMAS (PDA) WHO HAVE NOT RESPONDED TO PRIOR STANDARD TREATMENT. AUGUST 29, 2012 - A PHASE I/II, MULTI-CENTER TRIAL DESIGNED TO TEST THE SAFETY AND PRELIMINARY EFFICACY OF A FIRST IN CLASS CANCER TREATMENT OPENS AT TGEN / SCOTTSDALE HEALTHCARE CLINIC. PR610 IS DESIGNED TO ACTIVATE IN TISSUES WITH LOW LEVELS OF OXYGEN, WHICH IS CHARACTERISTIC OF MANY CANCERS. | |
| GRANT SUPPORT | GRANT FUNDING IS OFTEN THE LIFEBLOOD OF RESEARCH. IN 2012, TGEN INVESTIGATORS SUBMITTED 145 GRANTS TOTALING $115M. TGEN WAS AWARDED 9 GRANTS, TOTALING $1.4M, WITH AN ADDITIONAL 71 GRANTS PENDING AND IN REVIEWS TOTALING $70M. ADDITIONALLY, TGEN RECEIVED $12.8M FROM 2010 AND 2011 PENDING GRANTS, BRINGING THE AWARDED TOTAL FOR 2012 TO $14.2M. TGEN'S SUCCESS RATE CURRENTLY RESTS AT 23 PERCENT OF TOTAL GRANTS SUBMITTED, PLACING THE INSTITUTE NEARLY 3 PERCENT HIGHER THAN THE NATIONAL AVERAGE (NIH OVERALL SUCCESS RATE). 1. THREE-YEAR GRANT FROM STAND UP TO CANCER (SU2C) AND MELANOMA RESEARCH ASSOCIATION TOTALING $5,981,538 TO DR. JEFFREY TRENT FOR A PERSONALIZED MEDICINE STUDY OF PATIENTS WITH BRAF WILD-TYPE MELANOMA. 2. THREE-YEAR GRANT FROM THE MUSCULAR DYSTROPHY ASSOCIATION TOTALING $208,486 TO DR. LISA BAUMBACH-REARDON TO STUDY MUSCULAR DYSTROPHY. 3. UNDER SUBCONTRACT, A FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TOTALING $124,992 TO DR. MATTHEW HUENTELMAN TO STUDY ALZHEIMER'S DISEASE AND SUPPORT THE ARIZONA ALZHEIMER'S DISEASE CORE CENTER (ADCC). 4. FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $2.5 MILLION TO DR. MICHAEL BERENS TO SEARCH FOR NEW DRUG TARGETS IN GLIOBLASTOMA AND OTHER CANCERS THAT COULD BE SHARED WITH THE CANCER TARGET DISCOVERY AND DEVELOPMENT NETWORK. 5. THREE-YEAR GRANT UNDER SUBCONTRACT WITH THE UNIVERSITY OF MICHIGAN FROM SUSAN G. KOMEN FOR THE CURE TOTALING $533,180 TO DR. JEFFREY TRENT TARGETING STEM CELLS IN TRIPLE-NEGATIVE BREAST CANCER IN DIFFERENT RACIAL POPULATIONS, INCLUDING CLINICAL TRIALS. 6. TWO-YEAR GRANT FROM NATIONAL INSTITUTES OF HEALTH TOTALING $531,755 TO DR. PAUL KEIM TO STUDY CRYPTOCOCCUS GATTII BY SEQUENCING 200 GENOMES OF THIS TYPE OF FUNGUS, INCLUDING A PARTICULARLY VIRULENT AMERICAN STRAIN DESIGNATED AS VGIIC. 7. TWO-YEAR SUBCONTRACT GRANT (MAYO CLINIC IS PRIME) FROM ACCELERATE BRAIN CANCER CURE INC. TOTALING $262,480 TO DR. JOHN CARPTEN TO SHOW HOW WHOLE GENOME SEQUENCING CAN BE USED TO IDENTIFY CLINICALLY ACTIONABLE VULNERABILITIES IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS. 8. FOUR-YEAR GRANT FROM THE DEPARTMENT OF DEFENSE TOTALING $938,715 TO DR. PAUL KEIM TO CONDUCT GENOMIC PROFILES OF THE VARIOUS NEAR-NEIGHBOR FORMS OF THE PATHOGEN B. PSEUDOMALLEI, A BIOLOGICAL WARFARE AGENT. NAU IS PRIME ON THIS SUBCONTRACT. 9. UNDER SUBCONTRACT FROM THE UNIVERSITY OF GEORGIA, A FIVE-YEAR GRANT FROM THE NATIONAL CANCER INSTITUTE (NIH) TOTALING $663,574 TO DR. DANIEL VON HOFF TO IDENTIFY POTENTIAL GLYCOMARKERS FOR PANCREATIC AND BREAST CANCER IN AN EFFORT TOWARD EARLY CANCER DETECTION. 10. UNDER SUBCONTRACT FROM NAU, A FIVE-YEAR GRANT FROM THE NATIONAL SCIENCE FOUNDATION TOTALING $499,759 TO DR. LANCE PRICE TO STUDY MICROBIAL BIODIVERSITY IN RELATION TO SOIL CARBON CYCLES. | |
| ENTERPRISE EFFORTS, COLLABORATION AND JOB CREATION | TGEN'S OFFICES OF BUSINESS DEVELOPMENT AND TECHNOLOGY TRANSFER WORK TO DEVELOP AN APPROPRIATE ADMINISTRATIVE STRUCTURE TO HANDLE OMMERCIALIZATION OF ITS INTELLECTUAL PROPERTY, AS WELL AS DEVELOPING EFFECTIVE WAYS TO PARTNER WITH THE COMMERCIAL SECTOR. THE TECHNOLOGY TRANSFER OFFICE (TTO) FACILITATES AND ACCELERATES THE COMMERCIALIZATION OF TGEN'S SCIENTIFIC DISCOVERIES FOR THE BENEFIT OF HUMAN HEALTH BY: A. IDENTIFYING, PATENTING AND LICENSING NEW TECHNOLOGY; B. FACILITATING ACCESS AND EXCHANGE OF RESEARCH MATERIALS, TECHNOLOGIES, AND DATA VIA MATERIAL TRANSFER AGREEMENTS (MTAS) OR CONFIDENTIAL DISCLOSURE AGREEMENTS (CDAS); C. NEGOTIATING COLLABORATIVE RESEARCH AGREEMENTS; AND D. ASSISTING IN THE FORMATION OF START-UP COMPANIES WHEN APPROPRIATE. INVENTION DISCLOSURES TGEN SCIENTISTS WORK WITH THE OFFICE OF TECHNOLOGY TRANSFER (OTT) TO FILE INVENTION DISCLOSURES AS THE FIRST STEP TOWARD A POSSIBLE PATENT APPLICATION OR OTHER APPROPRIATE FORM OF INTELLECTUAL PROPERTY PROTECTION. TGEN FILED 24 INVENTION DISCLOSURES IN 2012 BASED ON DISCOVERIES STEMMING FROM TGEN-LED RESEARCH, AND 16 PROVISIONAL PATENT APPLICATIONS. SPIN OFFS TGEN FORMED ONE COMPANY (TRANSLATIONAL SYSTEMS LLC) IN 2012. CONTRACTS AND COLLABORATIONS TGEN SIGNED A TOTAL OF 434 CONTRACTS IN 2012, BROKEN DOWN AS FOLLOWS: A. 104 CONFIDENTIAL DISCLOSURE AGREEMENTS (CDA) B. 64 MATERIAL TRANSFER AGREEMENTS (MTA) C. 45 RESEARCH COLLABORATIONS (MANY WITH LOCAL AND STATE AFFILIATIONS), INCLUDING AGREEMENTS THAT FURTHER RESEARCH INTO A HOST OF DISEASES, INCLUDING BRAIN CANCER, MELANOMA, ALZHEIMER'S AND AUTISM. D. 29 CONSULTING AGREEMENTS E. 80 PROFESSIONAL SERVICES AGREEMENTS F. 4 COMMERCIALIZATION LICENSES G. 108 AGREEMENTS COVERING MISCELLANEOUS ACTIVITIES 1. MAYO CLINIC - "A PILOT STUDY EXAMINING THE UTILITY OF WHOLE GENOME TUMOR SEQUENCING (WGS) AND WHOLE GENOME EXPRESSION PROFILE TO FIND POTENTIAL TARGETS FOR THERAPY IN PATIENTS WITH ADVANCED CANCER" (DRS. CARPTEN, VON HOFF, RAMANATHAN & STEWART, BORAD, FONSECA, RAMANATHAN, VON HOFF). 2. MAYO CLINIC - CONTINUATION OF THE INTEGRATED CANCER GENOME RESEARCH FOCUSED ON NEXT-GENERATION SEQUENCING AND BIOINFORMATIC ANALYSIS. 3. CENTERS FOR DISEASE CONTROL RESEARCH (CDC) COLLABORATION AGREEMENT - PROJECTS INVOLVING ANTIBIOTIC-RESISTANT AND HEALTHCARE-ASSOCIATED BACTERIAL PATHOGENS (DRS. ENGELTHALER, LIMBAGO & MACCANNELL) 4. PHOENIX CHILDREN'S HOSPITAL RESEARCH PLAN 01 - PROFESSIONAL SERVICES PROVIDED TO TGEN BY DR. RATAN BHARDWAJ (DRS. BERENS & CRAIG) 5. SCOTTSDALE HEALTHCARE 2ND AMENDMENT TO RESEARCH PLAN 02 - EXTENDS TERM THROUGH 3/25/13 (DRS. BUSSEY & DEMEURE) 6. UNIVERSITY OF ARIZONA RESEARCH PLAN - "ASSESSING PRIMARY CILIA AND CENTROSOMES IN BASAL CELL CARCINOMA" (DRS. WEISS & MCDERMOTT) 7. MARICOPA INTEGRATED HEALTH SYSTEM (MIHS) AMENDMENT ONE TO RESEARCH COLLABORATION AGREEMENT - EXTENDS TERM THROUGH JUNE 20, 2015 8. PHOENIX CHILDREN'S HOSPITAL AMENDMENT ONE TO RESEARCH PLAN - "PROFESSIONAL SERVICES AGREEMENT FOR DR. RATAN BHARDWAJ" - REVISES PLANNING SUMMARY AND FINANCIAL PLAN (DRS. BHARDWAJ, CRAIG & BERENS) 9. VETERINARY NEUROLOGICAL CENTER RESEARCH COLLABORATION AGREEMENT & RESEARCH PLAN 01 - "CANINE BRAIN TUMOR DENDRITIC CELL VACCINE" (DRS. DECKER, CRAIG & BHARDWAJ) 10. TEXAS ENGINEERING EXPERIMENT STATION AMENDMENT THREE TO MEMORANDUM OF UNDERSTANDING (DR. DOUGHERTY) - 11. HILL'S PET NUTRITION RESEARCH - "EVALUATING THE IMPACTS OF PREBIOTICS AND PROBIOTICS ON THE FELINE GI MICROBIOME" (DR. PRICE) 12. MAYO CLINIC STATEMENT OF WORK 11 - "KNOWLEDGE MINING DATA FROM HT-RNAI SCREEN ON ANAPLASTIC THYROID CANCER CELLS" (DRS. COPLAND & KIEFER) 13. ILLUMINA AMENDMENT ONE TO STATEMENT OF WORK 3 - EXTENDS COLLABORATION PLANNING PERIOD THROUGH SEPTEMBER 17, 2012 14. SPECTRUM HEALTH HOSPITALS RESEARCH COLLABORATION AGREEMENT AND RESEARCH PLAN 01 - "UNDERSTANDING THE SHIFTS IN INTESTINAL GUT FLORA IN CHEMOTHERAPY PATIENTS AT RISK FOR INTESTINAL MUCOSITIS (DRS. PRICE & KURT) 15. MAYO CLINIC FIRST AMENDMENT TO RESEARCH PLAN (SELINSKY) - FOR PROJECT LUNG, EXTENDS TERM THROUGH DECEMBER 31, 2012 | |
| JOB CREATION | SEVEN NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED IN 2012 WITH SALARIES AND BENEFITS TOTALING $557,329. SALARIES FOR TEMPORARY POSITIONS (THOSE POSITIONS CREATED FOR A FINITE PERIOD OF TIME) TOTALED $106,745 AND STUDENT SALARIES WERE JUST OVER $332,469, BRINGING THE OVERALL TOTAL TO $996,543. THIS BROUGHT THE TOTAL FOR TGEN STAFF TO 257 IN 2012, OF WHICH 78 PERCENT HOLD A COLLEGE DEGREE AND 46 PERCENT HOLD AN ADVANCED DEGREE. 2012 POSITIONS FILLED (NEW AND REPLACEMENTS) INCLUDED: ADMINISTRATIVE ASSISTANT ASSISTANT DEVELOPMENT DIRECTOR ASSOCIATE BIOINFORMATICIAN BUSINESS ANALYST ENTERPRISE APPLICATIONS DIRECTOR LAB MANAGER POST-DOC FELLOW PROJECT ACCOUNTING DIRECTOR PURCHASING AGENT QUALITY ASSURANCE SPECIALIST RESEARCH ASSOCIATE RESEARCH ASSOCIATE II RESEARCH TECHNICIAN SOFTWARE ENGINEER SR. HIGH-PERFORMANCE COMPUTING ENGINEER STAFF SCIENTIST EDUCATION AND PUBLIC OUTREACH TGEN SCIENCE EDUCATION AND COMMUNITY OUTREACH IS GEARED TOWARD THE DEVELOPMENT OF A TALENTED BIOSCIENCE WORKFORCE IN ARIZONA, AND INCREASED PUBLIC FLUENCY IN GENOMIC SCIENCE AND TRANSLATIONAL MEDICINE. 2012 HIGHLIGHTS INCLUDE: INTERNSHIPS 2012 SAW 45 ARIZONA STUDENTS PARTICIPATE IN TGEN'S FLAGSHIP, PAID SUMMER INTERNSHIP PROGRAM, HELIOS SCHOLARS AT TGEN. COHORT DEMOGRAPHICS: 82 PERCENT ATTENDED PUBLIC ACADEMIC INSTITUTIONS; 27 PERCENT SELF-IDENTIFIED AS RACES/ETHNICITIES UNDERREPRESENTED IN THE BIOSCIENCES; 51 PERCENT ARE FEMALE; 13 PERCENT WERE IN HIGH SCHOOL, 82 PERCENT IN COLLEGE AND 5 PERCENT IN GRADUATE OR MEDICAL SCHOOL. TGEN BEGAN TO RE-ENGAGE THE NEARLY 250 HELIOS SCHOLARS ALUMNI BY DEVELOPING A TRACKING DATABASE AND HOSTING THE FIRST ALUMNI NETWORKING RECEPTION. TGEN INTENDS TO MAINTAIN RELATIONSHIPS WITH ALUMNI WHO CAN MENTOR CURRENT INTERNS AND ACT AS AMBASSADORS FOR ARIZONA BIOSCIENCES IN THEIR SOCIAL AND PROFESSIONAL NETWORKS. NEW IN 2012 IS THE IVY NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM, A SUMMER AND FALL PAID INTERNSHIP PROGRAM SUPPORTING THREE HIGH SCHOOL STUDENTS AND TWO UNDERGRADUATES ANNUALLY FOR NEUROLOGICAL DISEASE RESEARCH AND A CLINICAL TRAINING MODULE. TGEN PILOTED A PARTNERSHIP WITH DUKE UNIVERSITY TO BRING TWO DUKE UNDERGRADUATES INTERESTED IN BIOINFORMATICS AND GENOMICS TO STUDY AT TGEN FOR A 10-WEEK INTERNSHIP. THIS BROADENED AWARENESS OF TGEN NATIONALLY AND IT IS HOPED THAT STUDENT SHARING WILL SET THE STAGE FOR FUTURE FACULTY COLLABORATIONS. OUTSIDE OF THESE PROGRAMS, TGEN HOSTED APPROXIMATELY 15 SUMMER INTERNS, AND NEARLY 50 NON-PROGRAM ACADEMIC YEAR INTERNS THROUGHOUT ALL TGEN RESEARCH DIVISIONS INCLUDING LABORATORY AND CLINICAL RESEARCH, RESEARCH ADMINISTRATION, AND MATHEMATICS AND COMPUTATIONAL BIOLOGY RESEARCH. EDUCATIONAL TOURS TGEN HOSTED OVER 50 PUBLIC TOURS (500+ ATTENDEES) FOR STUDENTS, TEACHERS, COMMUNITY ORGANIZATIONS AND THE GENERAL PUBLIC. TGEN ALSO HOSTED AN IN-DEPTH PUBLIC TOUR, "DNA BY MOONLIGHT," WITH NEARLY 50 ATTENDEES IN SUPPORT OF THE INAUGURAL YEAR OF THE ARIZONA SCITECH FESTIVAL. IN MARCH 2012, TGEN SUPPORTED THREE LOCAL HIGH SCHOOL STUDENTS FROM THE BE A LEADER FOUNDATION FOR THE ANNUAL SHADOW A PROFESSIONAL DAY. | |
| COMMUNITY OUTREACH | TGEN FACULTY AND STAFF PARTICIPATED IN LOCAL, REGIONAL AND STATEWIDE SCIENCE FAIRS, AND SHARED INSIGHT AND RESEARCH INFORMATION AT COMMUNITY EVENTS, CAREER DAYS, EXPOS, AND EXPERT PANELS AT MIDDLE AND HIGH SCHOOLS, COMMUNITY COLLEGES, UNIVERSITIES, ETC. TGEN IS REPRESENTED ON THE LOCAL ARRANGEMENTS COMMITTEE, AND RECRUITS JUDGES AND VOLUNTEERS, FOR THE UPCOMING THREE-YEAR PHOENIX ROTATION OF THE INTEL INTERNATIONAL SCIENCE AND ENGINEERING FAIR. TGEN STAFF SERVED ON LOCAL ADVISORY COMMITTEES AND BOARDS IN SUPPORT OF SCIENCE EDUCATION SUCH AS THE ARIZONA SCIENCE CENTER PATHWAYS PROGRAM DESIGN TEAM, THE CHANDLER-GILBERT COMMUNITY COLLEGE BIOMEDICAL RESEARCH TECHNOLOGY PROGRAM ADVISORY BOARD, THE FLINN SCHOLARS PROGRAM REVIEW TEAM, AND SEVERAL OTHERS. MEDIA/ON-LINE TGEN REMAINS ACTIVE IN PURSING POSITIVE EARNED MEDIA EXPOSURE FOR THE INSTITUTE'S RESEARCH AND PHILANTHROPIC ACTIVITIES. MEDIA EXPOSURE RAISES AWARENESS AND BRINGS ADDED CREDIBILITY TO THE INSTITUTE AND THE STATE. IN TOTAL, TGEN RECEIVED GREATER THAN 1000 MEDIA MENTIONS IN 2012 IN VARIOUS TRADE AND PUBLIC MEDIA: LOCALLY, NATIONALLY AND INTERNATIONALLY. WHILE CITING TGEN SPECIFICALLY, THESE ARTICLES AND NEWS BRIEFS HELP BUILD A GREATER PRESENCE FOR THE CONTINUOUSLY EXPANDING BIOMEDICAL SCIENCE INITIATIVES OCCURRING IN ARIZONA. MEDIA OUTLETS INCLUDE: ABC NEWS, ARIZONA DAILY SUN, THE ARIZONA REPUBLIC, BLOOMBERG NEWS, THE BOSTON HERALD, CHICAGO TRIBUNE, CNN, DOW JONES, FLAGSTAFF TODAY, FORBES, THE INDEPENDENT (LONDON), KAET (CHANNEL 8), KNAU (FLAGSTAFF), KPNX (CHANNEL 12), THE LOS ANGELES TIMES, NEW YORK TIMES, NATIONAL PUBLIC RADIO, PHOENIX BUSINESS JOURNAL, PHOENIX MAGAZINE, USA TODAY, U.S. NEWS & WORLD REPORT, THE WASHINGTON POST, WIRED. A NEW LOGO AS TGEN ENTERS ITS SECOND DECADE, WE DO SO WITH A NEW LOGO AND WEBSITE THAT MORE SUCCINCTLY REFLECTS TGEN'S RESEARCH ENVIRONMENT AND MISSION AND THE RAPIDLY CHANGING TECHNOLOGIES THAT HAVE ACCELERATED OUR PACE OF DISCOVERY OVER THE PAST DECADE. THE NEW LOOK REFLECTS TGEN'S CONTINUED FOCUS ON THE PATIENT, PARTICULARLY IN THE AREAS OF CANCER, NEUROLOGY AND RARE CHILDHOOD DISORDERS. THESE CHANGES HAVE ALTERED THE PUBLIC VIEW OF HOW GENOMICS CAN POSITIVELY IMPACT SOCIETY IN TERMS OF MEDICAL CARE AND SO MANY ADDITIONAL FACETS OF LIFE. TGEN HAS ALWAYS BEEN FORWARD THINKING IN TERMS OF OUR RESEARCH AND ABILITY TO IMPACT PATIENT CARE, AND OUR NEW LOGO IS A FIRST STEP IN COMMUNICATING TO THE VARIOUS COMMUNITIES WITH INTEREST IN TGEN, THE VALUES THAT GUIDE OUR MISSION OF SETTING A NEW STANDARD OF CARE THROUGH THE EVOLUTION OF GENOMICS-BASED TECHNOLOGIES AND MEDICINE. THE NEW LOGO SHOWCASES THE INNOVATIVE SPIRIT OF TGEN, WHILE PAYING HOMAGE TO THE ORIGINAL LOOK BY INCORPORATING FORMS THAT COMPRISE THE ABSTRACT DEPICTION OF THE DOUBLE HELIX. THE CLEAN AND CONTEMPORARY (YET CLASSIC) DESIGN ILLUSTRATES THE ADVANCEMENT OF THE HEALTH AND SCIENCE FIELDS. THE INTERTWINING ELEMENTS EXEMPLIFY HOW HEALTH AND BIOLOGY WORK TOGETHER IN OUR MISSION TO TREAT AND CURE A VARIETY OF GENETIC DISEASES AND DISORDERS. REDEFINED ON-LINE PRESENCE WE'VE ALSO REDEFINED OUR ONLINE PRESENCE WITH A REDEVELOPED WEBSITE, THROUGH WHICH OUR VARIED STAKEHOLDERS CAN STAY UP-TO-DATE ON THE LATEST RESEARCH FINDINGS, PATIENT ADVANCES, PUBLIC EVENTS AND INITIATIVES. THE NEW WEBSITE MERGES THE TGEN AND TGEN FOUNDATION WEBSITES INTO ONE, WHICH MAKES IT EASIER TO LEARN ABOUT AND SUPPORT THE MISSION OF TGEN. OUR NEW IDENTITY RETAINS THE QUALITIES OF OUR BRAND PROMISE BUT REFLECTS OUR EVOLUTION OVER THE PAST DECADE IN BECOMING LEADERS IN THE AREA OF PERSONALIZED MEDICINE. THE NEW TGEN WEBSITE ALSO INCORPORATES THE USE OF RESPONSIVE DESIGN, AN INNOVATIVE LAYOUT DESIGN THAT ALLOWS THE WEBSITE TO BE PROPERLY RENDERED ON ALL DEVICE TYPES, SO THAT VISITORS TO THE SITE ARE ENSURED A POSITIVE BROWSING EXPERIENCE FROM BOTH AN AESTHETIC AS WELL AS A NAVIGATIONAL PERSPECTIVE. | |
| CONSOLIDATED AUDITED FINANCIAL STATEMENTS | FORM 990, PART IV, LINE 12B | CONSOLIDATED AUDITED FINANCIAL STATEMENTS WERE ISSUED FOR THE 13-MONTH PERIOD ENDING DECEMBER 31, 2012. THE TAX YEAR BEING REPORTED FOR THIS FORM 990 IS FOR THE YEAR ENDED NOVEMBER 30, 2012. PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 FORM 990, PART VI, LINE 11A THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE 990 IS THEN REVIEWED BY MANAGEMENT IN THE FINANCE DEPARTMENT AND POSTED ON THE BOARD WEBSITE PRIOR TO FILING WITH THE IRS. |
| PROCESS USED TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST | FORM 990, PART VI, LINE 12C | TGEN FOUNDATION ISSUES A CONFLICT OF INTEREST QUESTIONNAIRE ON AN ANNUAL BASIS TO ALL FOUNDATION DIRECTOR LEVEL POSITIONS AND ABOVE IN ADDITION TO ANY KEY EMPLOYEES DESIGNATED BY THE FOUNDATION PRESIDENT AND/OR TGEN CHIEF OPERATING OFFICER. THE QUESTIONNAIRES ARE REVIEWED BY THE TGEN CHIEF FINANCIAL OFFICER AND THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE FOUNDATION PRESIDENT AND/OR TGEN CHIEF OPERATING OFFICER TO ENSURE A PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS NEEDED BASIS BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. |
| PROCESS USED TO DETERMINE COMPENSATION | FORM 990, PART VI, LINES 15A AND 15B | TGEN FOUNDATION DOES NOT HAVE ANY DIRECT EMPLOYEES. COMPENSATION IS DETERMINED BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USING THE FOLLOWING PROCESS: TGEN'S GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE WILL ACT IN AN "ADVICE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSONS AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL BOARD FOR APPROVAL. DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS. DURING THE DECISION-MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS WHEN DEEMED NECESSARY AND ADVISABLE. THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING DISQUALIFIED PERSONS' COMPENSATION". WHEN DEVELOPING A COMPENSATION PHILOSOPHY, TGEN KEPT IN MIND THE FOLLOWING FACTORS: THE TGEN MISSION AND STRATEGY THE TGEN CULTURE TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT TRENDS IN RECRUITMENT OF NEW EMPLOYEES TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER TGEN'S LIFE CYCLE STAGE |
| AVAILABILITY OF CERTAIN DOCUMENTS TO THE GENERAL PUBLIC | FORM 990, PART VI LINE 19 | TGEN FOUNDATION PROVIDES ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY TO THE GENERAL PUBLIC UPON REQUEST. |
| HOURS DEVOTED TO RELATED ORGANIZATION | FORM 990, PART VII | THE ORGANIZATION DOES NOT DIRECTLY HAVE ANY EMPLOYEES. THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ARE PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN FOUNDATION: MICHAEL BASSOFF DENISE MCCLINTIC MICHAEL BASSOFF DEVOTES 24 HOURS PER WEEK TO TGEN FOUNDATION AND 16 HOURS PER WEEK TO TGEN. DENISE MCCLINTIC DEVOTES 40 HOURS PER WEEK TO TGEN FOUNDATION AND NO HOURS PER WEEK TO TGEN. THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ARE PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN: JEFFREY TRENT TERESA BURLESON ELIZABETH MONTEMAYOR THEY DEVOTE 39 HOURS PER WEEK TO TGEN AND 1 HOUR PER WEEK TO TGEN FOUNDATION. |
Schedule R IRS990ScheduleR
Form990 Schedule R Part II Form990ScheduleRPartII (2 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EINEIN | Primary ActivitiesPrimaryActivities | Legal Domicile StateLegalDomicileState | Exempt Code SectionExemptCodeSection | Public Charity StatusPublicCharityStatus | Business Name Line1DirectControllingEntityName/BusinessNameLine1 | Controlled OrgControlledOrg |
|---|---|---|---|---|---|---|---|---|---|---|
| THE TRANSLATIONAL GENOMICS RESEARCH INST | ||||||||||
| 445 NORTH 5TH STREET | PHOENIX | AZ | 85004 | 753065445 | RESEARCH | AZ | 501(C)(3) | 7 | NA | false |
| VAN ANDEL RESEARCH INST (THRU 31212) | ||||||||||
| 333 BOSTWICK AVE STE 850 | GRAND RAPIDS | MI | 49503 | 522000823 | MEDICAL RSCH | MI | 501(C)(3) | 4 | NA | false |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Ann Rents Royalties | false | ReceiptOfIntAnnRentsRoyalties |
| Gift Grant Or Cap Contr To Other Org | true | GiftGrantOrCapContrToOtherOrg |
| Gift Grant Or Cap Contr Fr Other Org | false | GiftGrantOrCapContrFrOtherOrg |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrg |
| Loans Or Guarantees From Other Org | false | LoansOrGuaranteesFromOtherOrg |
| Sale Of Assets To Other Org | false | SaleOfAssetsToOtherOrg |
| Purchase Of Assets From Other Org | false | PurchaseOfAssetsFromOtherOrg |
| Exchange Of Assets | false | ExchangeOfAssets |
| Rental Of Facilities To Other Orgs | false | RentalOfFacilitiesToOtherOrgs |
| Rental Of Facilities Fr Other Orgs | false | RentalOfFacilitiesFrOtherOrgs |
| Perform Of Services For Other Orgs | true | PerformOfServicesForOtherOrgs |
| Perform Of Services By Other Orgs | false | PerformOfServicesByOtherOrgs |
| Sharing Of Facilities | false | SharingOfFacilities |
| Sharing Of Paid Employees | false | SharingOfPaidEmployees |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrg |
| Reimbursement Paid By Other Org | true | ReimbursementPaidByOtherOrg |
| Other Transfer To Other Org | false | OtherTransferToOtherOrg |
| Other Transfer From Other Org | false | OtherTransferFromOtherOrg |
Comments